Should I consider a cancer clinical trial?

What question is the trial asking?

Ask what researchers are trying to establish. They may be comparing treatments, studying a new combination or finding out how safely a treatment can be given.

Early-phase drug trials often examine dose and safety; later phases may compare outcomes with established treatment. Phases can overlap and designs differ. Not every study is randomised or blinded, and a phase number does not guarantee benefit or safety. Read the information for the actual study.

Would I receive the new treatment?

Not necessarily. In a randomised trial, allocation to a group is determined by chance rather than the doctor's preference. You may receive the standard treatment being used for comparison.

Some trials use a placebo; many do not. It may be added to standard treatment as a comparison with a new drug added to the same treatment. It does not routinely replace established effective cancer treatment. Ask exactly what each group receives, why the comparison is appropriate and whether you and the clinicians will know the allocation.

Why might I not be eligible?

Trials have entry criteria to answer a defined question and protect participants. These can involve cancer type, previous treatment, test results, general health and organ function.

A study listed online may not be open at your hospital, may have stopped recruiting or may not fit your situation. Your team can help assess relevance and whether referral to another centre is appropriate.

Consider the practical burden

Extra visits, tests, travel and paperwork may be involved. Possible benefits need to be considered alongside side effects, uncertainty and the time required.

Ask which costs, if any, are reimbursed. Do not assume travel or accommodation will be covered. Also ask who provides routine care and whom to call if symptoms develop.

Consent and changing your mind

The research team should explain the study before you decide. Participation is voluntary, and you can leave without giving a reason. Tell the team so they can arrange safe treatment changes and discuss whether you want any study follow-up to continue.

Leaving trial treatment or participation does not automatically mean information already collected will be deleted. What is retained or used depends on the study, its legal basis and applicable rules. Ask for the participant information and privacy notice to explain this, including any choices about further data collection.

Choosing not to participate should not remove your access to appropriate usual care.

A useful appointment ends with an understanding of the trial's question, alternatives, likely burden and important unknowns. Informed consent explains the wider treatment discussion.